戻る
Black Diamond Therapeutics Stock Advances on Silevertinib Progress and Strategic Restructuring
戻る
株式ニュース
テーマ
Black Diamond Therapeutics Stock Advances on Silevertinib Progress and Strategic Restructuring
Black Diamond Therapeutics Stock Advances on Silevertinib Progress and Strategic Restructuring
Edgen Stock
·
Sep 08 2025, 18:45
共有先
共有先
リンクをコピー
ソース:
[1] BDTX Stock Surges 51.1% in Six Months: Is There More Room for Growth?
[2] Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
[3] Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy